UBS stuft Par Pharma von buy auf neutral.
(© BörseGo AG 2012 - Autor: Tobias Krieg, Redakteur)
| 37,931 Euro | -0,903 -2,33 % | ||
| WKN: A0B5R1 ISIN: US69888P1066 Ticker-Symbol: N/A | Frankfurt | 28.09.12 | 08:03 Uhr |
Branche PharmaAktienmarkt nicht mehr börsennotiert |
|
UBS stuft Par Pharma von buy auf neutral.
| Zeit | Aktuelle Nachrichten | |
|---|---|---|
| 22.05. | Par Pharmaceutical Begins Shipment of Generic Atacand | |
| WOODCLIFF LAKE, N.J., May 22, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca... Mehr lesen zu: Par Pharmaceutical Begins Shipment of Generic Atacand | ||
| 08.05. | Par Pharmaceutical Announces Quarterly Conference Call | |
| WOODCLIFF LAKE, N.J., May 8, 2013 /PRNewswire/ --Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, May 16, 2013, at 10:00 a.m. EDT to review its results... Mehr lesen zu: Par Pharmaceutical Announces Quarterly Conference Call | ||
| 21.03. | Par Pharmaceutical Companies Management Discusses Q4 2012 Results - Earnings Call Transcript | |
Mehr lesen zu: Par Pharmaceutical Companies Management Discusses Q4 2012 Results - Earnings Call Transcript | ||
| 15.03. | FDA approves Par Pharma fluvoxamine maleate ER capsules ANDA | |
Mehr lesen zu: FDA approves Par Pharma fluvoxamine maleate ER capsules ANDA | ||
| 14.03. | Par Pharmaceutical Begins Shipment of Generic Luvox CR | |
| WOODCLIFF LAKE, N.J., March 14, 2013 /PRNewswire/ --Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated... Mehr lesen zu: Par Pharmaceutical Begins Shipment of Generic Luvox CR |
